{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:29:31Z","timestamp":1759336171790},"reference-count":23,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.4155\/bio-2016-0253","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T15:15:39Z","timestamp":1494861339000},"page":"609-619","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Determination of Naloxegol in Human Biological Matrices"],"prefix":"10.1080","volume":"9","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Clinical Sample Science, Early Clinical Development, AstraZeneca, 35 Gatehouse Drive, Waltham, MA02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Covance Laboratories, Inc., 3301 Kinsman Blvd, Madison, WI53704, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Severin","sequence":"additional","affiliation":[{"name":"Covance Laboratories, Inc., 3301 Kinsman Blvd, Madison, WI53704, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2008.00495.x"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.019"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2009.0014"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.30"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.592830"},{"key":"e_1_3_2_8_1","unstructured":"Moventig (Naloxegol)\u2122 Prescribing Information. AstraZeneca AB S\u00f6dert\u00e4lje Sweden (2014). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002810\/WC500179075.pdf"},{"key":"e_1_3_2_9_1","unstructured":"Movantik (Naloxegol)\u2122 Prescribing Information. AstraZeneca AB Ontario Canada (2015). www.azpicentral.com\/movantik\/movantik.pdf"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202276"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310246"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.04.024"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.206"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.204"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.613"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12756"},{"key":"e_1_3_2_17_1","volume-title":"Guideline on the Investigation of Bioequivalence","year":"2010","unstructured":"Guideline on the Investigation of Bioequivalence . European Medicines Agency (EMA), London, United Kingdom (2010). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf"},{"key":"e_1_3_2_18_1","volume-title":"Guidance for Industry: Bioanalytical Method Validation","year":"2001","unstructured":"Guidance for Industry: Bioanalytical Method Validation . US Food and Drug Administration (FDA), MD, USA (2001). www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf"},{"key":"e_1_3_2_19_1","volume-title":"Guidance for ndustry: Bioanalytical Method Validation (Draft Guidance)","year":"2013","unstructured":"Guidance for ndustry: Bioanalytical Method Validation (Draft Guidance) . US Food and Drug Administration (FDA), MD, USA (2013). www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.348"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.349"},{"key":"e_1_3_2_22_1","volume-title":"Guideline on Bioanalytical Method Validation","year":"2015","unstructured":"Guideline on Bioanalytical Method Validation . European Medicines Agency (EMA), London, UK (2015). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf"},{"key":"e_1_3_2_23_1","volume-title":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies","year":"2012","unstructured":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies . Health Canada, Ottawa, Ontario, Canada (2012). www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/applic-demande\/guide-ld\/bio\/gd_cbs_ebc_ld-eng.pdf"},{"key":"e_1_3_2_24_1","volume-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs Or INDs \u2013 General Considerations (Draft Guidance)","year":"2014","unstructured":"Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs Or INDs \u2013 General Considerations (Draft Guidance) . US Food and Drug Administration (FDA), MD, USA (2014). www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm389370.pdf."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.693"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/bio-2016-0253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:21:58Z","timestamp":1715984518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/bio-2016-0253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.4155\/bio-2016-0253"],"URL":"https:\/\/doi.org\/10.4155\/bio-2016-0253","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}